-
Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
Commercial Launch Announcement Marks a New Chapter for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) — FDA-Approved Preservative-Free Ketamine Now Being Sold, 17-Person National Sales Team Activated, Market Relationships Cover Approximately 80% of U.S. Ke. Read more
-
S&P 500's 4.4% Plunge: Buy the Dip or Wait? KayeDinero Spotlights TrendSetter
The Asheville artist spotlights her TradingView indicator alongside new song "Humble Pie" and a Blue Ridge fall-color aerial film.. Read more
-
FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Also Received an $11 Million Dollar Award for Robotic Magnetic Stimulation with Pharma Treatment for Resistant Depression. Read more
-
Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
A Landmark October 30th FDA Approval, Commercial Manufacturing Readiness, Two-Year Stability Results, and an $11.25 Million DARPA Research Contract Put NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) at an Important Turning Point in Its Growth. Read more
-
Expanding Into Medically Supervised Wellness With Major Apollo Wellness Centers Announcement; Sibannac, Inc. (Stock Symbol: SNNC)
$SNNC acquires Majority Stake in New Joint Venture With Doc-Rx Opens the Door to Telehealth, U.S.-Made Peptides and an Ambitious Wellness Clinic Expansion Strategy. Read more
-
Dynamic Relaunch as AI Predictive Cybersecurity Company Optimized to Prevent Threats Proactively: Cycurion, Inc. (N A S D A Q: CYCU)
$CYCU Boasts a 30 Million Annual Run Rate After Signing Largest Contract Ever, Valued Over $54 Million. Read more
-
With Oil Prices Surging…Sky Quarry's Nevada Refinery Is Back in Action — CEO Highlights a Powerful New Growth Chapter for (N A S D A Q: SKYQ)
Eagle Springs has restarted with a 5,000-barrel-per-day capacity, a proposed $50 million non-dilutive Nevada oil initiative and a substantial Utah resource opportunity, Sky Quarry $SKYQ is advancing its vision of a more integrated Western U.S. energy plat. Read more
-
450 Million Revenue Run Rate, Global Telecom Reach and a New Digital Growth Opportunity Take Center Stage: IQSTEL, Inc. (N A S D A Q: IQST)
With relationships spanning 600 telecommunications operators, a potential reach of 2.3 billion end users, and fresh momentum in mobile entertainment, IQSTEL is advancing its strategy to transform a substantial telecommunications platform into a higher-mar. Read more
-
Commercial Manufacturing Validation Completed as November 10 FDA Milestone Approaches; Critical FDA Milestone Close: NRx Pharmaceuticals NAS DAQ: NRXP
NRXP Reports Three Successfully Manufactured Commercial Lots, Two-Year Stability Data, and Commercially Releasable Supply Pending FDA Approval — While an $11.18 Million DARPA Contract Expands the Company's Research Opportunities. Read more
-
Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)
October 15 FDA Update Confirms Minor Labeling Changes Ahead of November 10 Goal Date, While an $11.18 Million DARPA Contract and Innovative Depression Research Expand the Company's Potential. Read more
-
Sky Quarry's Big Turning Point: CEO Marcus Laun Outlines the Next Phase for N A S D A Q: SKYQ
New SmallCapVoice interview with $SKYQ puts the spotlight on a restarted Nevada refinery, 5,000-barrel-per-day potential, a non-dilutive $50 million oil-development initiative and Sky Quarry's plans to ramp both Nevada and Utah operations.. Read more
-
$11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
Today's landmark defense contract launches the FDA-approved SPARC-TMS trial while NRx simultaneously advances its preservative-free ketamine program, HOPE Therapeutics and an expanding CNS pipeline. Read more
-
Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
As fentanyl continues to drive an enormous public-health challenge in the United States, Nutriband's AVERSA™ technology is being developed to address a different but important piece of the problem: abuse, misuse, diversion and accidental exposure involvin. Read more
-
Growth Story Expands: $54.6M Contract, $30M Revenue Run Rate, 800+ Customers, 50+ Patents & New AI Cybersecurity Products for Cycurion, Inc $CYCU
Cycurion, Inc. (N A S D A Q: CYCU) Expands From Government Cybersecurity Into Public Safety, Healthcare, AI, Fleet Analytics and Commercial Markets as Q2 Margins Surge Nearly 5X and Management Authorizes $500K Share Repurchases. Read more
-
Sky Quarry Restarts Nevada's Only Crude Oil Refinery — A Major New Chapter Begins in This Highly Lucrative sector for N A S D A Q: SKYQ
Today's air-permit approval and immediate Eagle Springs restart mark a major operational milestone, while 5,000-barrel-per-day capacity, 15,000 barrels of crude inventory, Nevada oil-development plans and a tightening Western refining market put Sky Quarr. Read more
-
Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
$NTRB reaches a new 52-week high of $9.00 and closes at $8.99, extending a powerful September advance as the company approaches the September 30 expiration of 910,904 publicly traded warrants and continues advancing its AVERSA™ abuse-deterrent transdermal. Read more
-
Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)
Today's Proposed Combination Could Significantly Expand CDIX's Healthcare Footprint — While New Equity, Warrants and Exercise Activity Put the Capital Structure Squarely in Focus. Read more
-
Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
New worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's platform, creating a potential path from patient subtypes and biomarkers to biological mechanisms and therapeutic targets. Positioned for $400M to $1.2 Billion US Coun. Read more
-
Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
With $NTRB shares gaining significant momentum in September, investors are watching a rapidly approaching warrant expiration, new intellectual-property progress for Nutriband's abuse-deterrent fentanyl platform, strengthening visibility through Nasdaq's b. Read more
-
Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
With a potential Q4 commercial launch, expanding diagnostic opportunities, a major telehealth platform, veterinary oncology initiatives and a proposed Xycota acquisition, NexTel is positioning $MAJI around multiple potential growth catalysts. Read more
-
European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
Today's GeNeuro patent milestone adds a potentially significant ALS opportunity to an already expanding NRx platform, while HOPE Therapeutics advances robotic TMS deployment and the company's preservative-free ketamine program moves closer to commercializ. Read more
Your online source of trusted news